Mode
Text Size
Log in / Sign up
Phase 2 N=32 Treatment

Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer

Hormone Refractory Prostate Cancer

Enrolled (actual)
32
Serious AEs
9.4%
Results posted
Apr 2023
Primary outcome: Primary: Number of Participants With Stable, Decreased, or Increased PSA Doubling Times (PSADT) — 7; 2; 17 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
ADENOVIRUS/PSA VACCINE (Biological)
Age
Adult, Older Adult · 18+ yrs
Sex
Male
Sponsor
David M Lubaroff
Primary completion
Dec 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Stable, Decreased, or Increased PSA Doubling Times (PSADT)
7; 2; 17
PRIMARY
Number of Participants Who Develop a Strong or Modest Anti-PSA Immune Response
15; 3
SECONDARY
Number of Participants Alive and Deceased Following Treatment
25; 3; 20; 8; 12; 16

Summary

This investigational study involves treatment with an Ad/PSA vaccine for men with prostate cancer who present with evidence of hormone refractory metastatic disease.

Eligibility Criteria

Inclusion criteria

  • Men with prostate cancer who present with evidence of hormone refractory disease (D3).
  • Men with a positive bone scan or a positive CT scan (with obvious soft tissue metastasis or lymph nodes >1 cm), a PSA doubling time of >/= 6 months, and a total PSA of /= 18 years.
  • Required laboratory values (obtained within 2 weeks of initiation of treatment)
  • Serum creatinine /= 1800 per mm3, platelets >/= 100,000 per mm3, WBC >/= 3700, and lymphocytes >590.
  • Adequate hepatocellular function: AST <3x upper limit of normal and total bilirubin <1.5 mg/dl (unless bilirubin elevation is consistent with Gilbert's syndrome).
  • Castrate levels of testosterone of </= 50 ng/ml.
  • PSA can be used as an eligibility criterion must be drawn within 28 days prior to injection number 1 and will be drawn on Day 1 for use as a baseline value.

Exclusion criteria

  • Active or unresolved clinically significant infection.
  • Parenteral antibiotics <7 days prior to initiation of treatment.
  • Evidence of prior or current CNS metastases. Specific imaging is not necessary in the absence of signs or symptoms.
  • Co-morbid medical conditions which would result in a life expectancy (participation) of less than 1 year.
  • Patients with compromised immune systems; congenital, acquired, or drug-induced (immunosuppressive agents) will be excluded from the study. Use of prednisone at doses higher than 10 mg daily (or equipotent steroid doses) for more than 7 days within 3 months of initiation of treatment is not allowed.
  • Pre-existing malignancies that required treatment within the past 5 years except for basal or squamous cell cancers of the skin.
  • Prior participation in any vaccine studies for non-infectious diseases.
  • Prior chemotherapy, defined as prior cytotoxic chemotherapy for prostate cancer (or any cancer unless more than 5 years have elapsed). Examples of cytotoxic chemotherapy are mitoxantrone/prednisone and taxanes. Drugs such as Casodex or ketoconazole treatment must have been completed at least 6 weeks prior to initiation of treatment.
  • The inability to understand the language and the clinical protocol.
  • Allergy or religious objection to pork products; Gelfoam is produced from pork.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00583024). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search